Genesys Capital:

Life science venture capital

We invest in early stage life science companies that are poised to change lives for the better.

About Genesys

Expertise. Experience. Insight.

Genesys Snapshot:

  • $300M+ Raised
  • $250M+ Invested
  • 5 Funds
  • 38 Companies
  • 18 Exits

Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.

Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.

Why Genesys succeeds

Robust industry relationships, deep subject area knowledge, and proven insights let us identify viable companies early… and arm them to perform.

Stable and proven team

Our team has worked together for two decades of successful and continuous partnership.

Robust industry relationships

Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.

Proven strategy and profitable returns

We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.

Essential expertise for scale

We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.

Our Team

Expertise. Experience. Insight.

Deep subject knowledge, Robust industry relationships, Proven insight — meet the Genesys team.

The Genesys Team

Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.

  • Jennifer Williams

    Jennifer Williams

    Director of Finance and Operations

  • Damian Lamb

    Damian Lamb

    Co-founder, Managing Director

  • Jamie Stiff

    Jamie Stiff

    Managing Director

  • Kelly Holman

    Kelly Holman

    Co-founder, Managing Director

  • Lisa Low

    Lisa Low

    Chief Financial Officer

  • Maxime Ranger

    Maxime Ranger

    Venture Partner

  • Sarah Farr

    Sarah Farr

    Associate

  • Mariya Valerova

    Mariya Valerova

    Office Manager

  • Paras Sharma

    Paras Sharma

    Associate

Our Portfolio

$250M invested
38 Companies
18 Exits

Our track record is a direct result of our approach to investment and company building.

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

MONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).

Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. As Chief Medical Officer

HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.

Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors

MONTREAL (CANADA) – October 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion.

Adapsyn Bioscience receives funding to discover novel therapeutics for tuberculosis

HAMILTON, ON, Oct. 18, 2022 /CNW/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced that it has received funding from the Bill & Melinda Gates Foundation to find novel therapeutics that target tuberculosis...

Inversago Pharma Raises $95 million CAD in Series C Financing

MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”).

Inversago Pharma Awarded the 'Promising Health Biotech Company of the Year' Gold Leaf Award at the BIONATION Conference in Ottawa

MONTREAL (CANADA) – September 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the 'Promising Health Biotech Company of the Year' Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada.

Adapsyn Bioscience enters into strategic collaboration with Evotec

HAMILTON, ON, Sept. 21, 2022 /PRNewswire/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration with Evotec SE...

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

MONTREAL (CANADA) – September 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company's lead program.

For older news items, visit the Genesys News Archive here

Contact us

We’re listening!

Genesys Capital is located at Front St and University Ave in downtown Toronto, in the heart of the life science hub.